Floatz logo

eci830

Advanced CCNE1-amplified Solid Tumors

Novartis PharmaceuticalsPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Advanced CCNE1-amplified Solid Tumors cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Novartis Pharmaceuticals
Phase 1/2CC
Ribociclib
Novartis Pharmaceuticals
Phase 1/2CC
erw316
Novartis Pharmaceuticals
Phase 1/2CC
Letrozole
Novartis Pharmaceuticals
Phase 1/2CC
gvv858
Novartis Pharmaceuticals
Phase 1/2CC
LEUPROLIDE
Novartis Pharmaceuticals
Phase 1/2CC
Zoladex
Novartis Pharmaceuticals
Phase 1/2CC

Same molecule, other indications

eci830 is also rated in:

Advanced HR+/HER2- Breast CancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →